SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-21-000063
Filing Date
2021-03-19
Accepted
2021-03-19 16:08:40
Documents
15
Period of Report
2021-03-18
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20210318.htm   iXBRL 8-K 43766
2 EX-3.1 exhibit-31xzntlxamendedres.htm EX-3.1 241132
  Complete submission text file 0001725160-21-000063.txt   480371

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20210318.xsd EX-101.SCH 2423
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT zntl-20210318_cal.xml EX-101.CAL 710
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20210318_def.xml EX-101.DEF 1643
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20210318_lab.xml EX-101.LAB 27005
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20210318_pre.xml EX-101.PRE 14272
8 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20210318_htm.xml XML 12257
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 21758250
SIC: 2834 Pharmaceutical Preparations